Sionna Therapeutics SION
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Sionna Therapeutics (SION) Business Model and Operations Summary
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
Key Insights
Sionna Therapeutics (SION) Core Market Data and Business Metrics
Latest Closing Price
$13.69Market Cap
$576.72 MillionAverage Trade Volume
251,800 SharesTotal Outstanding Shares
44.12 Million SharesCEO
Mr. Michael Cloonan M.B.A.Total Employees
48IPO Date
February 7, 2025SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
21 Hickory Drive, Suite 500, Waltham, MA, 02451
Earnings Reports
Expected vs. Actual Quarterly Earnings-Per-Share & Revenue
Short Volume
Daily short volume activity identifies short-term trading pressure and potential price volatility
Revenue Breakdown
Distribution of revenue across unique business segments & geographies
Historical Stock Splits
| Execution Date | Split Amount |
|---|